Loading
companiesCompany
Hikma Pharmaceuticals
Hikma is one of the largest makers of generic sterile injectables for US hospitals, including many chemotherapy and supportive-care drugs, from plants in Ohio, New Jersey and Portugal.
Overview
Hikma Pharmaceuticals, founded in Amman in 1978 and listed in London, supplies hundreds of injectable generics to hospitals in the United States and elsewhere, among them oncology drugs and the antiemetics, steroids and anti-infectives given alongside them. Its injectables plants in Columbus, Ohio, Cherry Hill, New Jersey, and Portugal are the kind of sterile capacity that determines whether a shortage of a low-margin cancer drug can be filled by a second supplier.
Headquarters
London, GB
Scorecard
All companies#100of 1244 companies, score 50
- approved products +12
- modalities +4
- regions +2
- 24-month regulatory events +2
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 0 targets, 2,734 registry studies. Formula on the scorecards page.
Type
Large pharma · HIK
Stage
Public
Website
Founded
1978
Approved5-HT3 receptor antagonist (antiemetic)
Ondansetron · Zofran
Ondansetron (Zofran) was the drug that made cisplatin-type chemotherapy bearable. It blocks the serotonin signal that triggers vomiting and is now a cheap generic tablet, dissolving wafer or injection used across cancer care.
ApprovedGlucocorticoid
Dexamethasone · Decadron (historic) / Hemady / Neofordex
Dexamethasone is a long-acting glucocorticoid steroid that kills lymphoid cancer cells directly, which is why it sits in nearly every myeloma regimen and in childhood leukaemia and lymphoma protocols. It is also the standard drug for preventing chemotherapy sickness and for brain swelling and spinal cord compression; high blood sugar, insomnia, muscle wasting and infection follow prolonged use.
Similar pages
- CompanyAmneal Pharmaceuticals
Shares Generic oncology drug supply and shortage mitigation, Generic sterile injectables (the 2023 platinum shortage) and the tag manufacturing-wave.
- TechnologyBCG manufacturing and the bladder cancer BCG shortage
Shares Generic oncology drug supply and shortage mitigation and the tag manufacturing-wave.
- TechnologyOral solid dose manufacturing (tablets and capsules)
Shares Ondansetron, Dexamethasone and the tag manufacturing-wave.
- TechnologyGMP, inspections, Form 483s and warning letters
Shares Generic oncology drug supply and shortage mitigation, Generic sterile injectables (the 2023 platinum shortage) and the tag manufacturing-wave.
- TechnologySmall-molecule API synthesis
Shares Generic oncology drug supply and shortage mitigation, Generic sterile injectables (the 2023 platinum shortage) and the tag manufacturing-wave.
- TechnologymRNA and lipid nanoparticle manufacturing
Shares Sterile fill-finish and lyophilisation and the tag manufacturing-wave.
- TechnologyDownstream purification (Protein A capture, viral clearance, polishing)
Shares Sterile fill-finish and lyophilisation and the tag manufacturing-wave.
- TechnologyBiosimilar manufacturing and comparability
Shares Sterile fill-finish and lyophilisation and the tag manufacturing-wave.
technologies
drugs
ApprovedGlucocorticoid
Dexamethasone · Decadron (historic) / Hemady / Neofordex
Approved5-HT3 receptor antagonist (antiemetic)
Ondansetron · Zofran